Waters Gains CE Mark for BD BACTEC FXI, Bolstering Clinical Diagnostics Portfolio
Event summary
- Waters Corporation received CE marking for the BD BACTEC FXI Culture System, enabling commercialization in Europe.
- The new system reduces time to pathogen detection by approximately 3 hours (~15%) compared to the previous generation.
- A key innovation is automated blood volume measurement, addressing a common source of diagnostic error (up to 85% of vials improperly filled).
- The system features a capacity of up to 960 vials per module, designed for high-throughput microbiology labs.
The big picture
The acquisition of BD Biosciences and Diagnostic Solutions by Waters signals a strategic shift towards expanding its presence in the high-growth clinical diagnostics market. The BD BACTEC FXI system addresses a critical need for faster and more accurate sepsis diagnostics, a market driven by increasing mortality rates and the imperative for antimicrobial stewardship. This move positions Waters to capitalize on the rising demand for automated, high-throughput testing solutions within the broader life sciences sector.
What we're watching
- Market Adoption
- The speed of adoption in Europe will depend on lab infrastructure upgrades and reimbursement policies, potentially limiting initial revenue gains despite regulatory clearance.
- Regulatory Expansion
- Success in securing approvals in other key global markets, particularly the US, will be crucial for realizing the full potential of the BD BACTEC FXI system.
- Competitive Landscape
- How Waters and BD manage the transition of manufacturing and regulatory responsibilities will impact the system's reliability and Waters' ability to compete with established players in clinical microbiology.
Related topics